Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 3, 2012, Pages 267-270

  Queenan, Anne Marie ^a   Pillar, Chris M ^b,c   Deane, Jennifer ^b   Sahm, Daniel F ^b   Lynch, A Simon ^a   Flamm, Robert K ^a,d   Peterson, Janet ^a   Davies, Todd A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Eurofins Medinet Inc   (Germany)

^c Micromyx LLC   (United States)

^d JMI LABORATORIES   (United States)

Author keywords

Acinetobacter; Multidrug resistance; US Surveillance

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTAZIDIME; COLISTIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DEMOGRAPHY; DRUG CHOICE; DRUG EFFICACY; FEMALE; GERIATRIC PATIENT; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PUERTO RICO; TREND STUDY; UNITED STATES; WARD;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; POPULATION SURVEILLANCE; PUERTO RICO; UNITED STATES; YOUNG ADULT;

EID: 84862198074     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.04.002     Document Type: Article

References (17)

1. Adams-Haduch J.M., Onuoha E.O., Bogdanovich T., Tian G.-B., Marschall J., Urban C.M., Spellberg B.J., Rhee D., Halstead D.C., Pasculle A.W., Doi Y. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clinical Microb 2011, 49:3849-3854.
2. Chuang Y.-C., Sheng W.-H., Li S.-Y., Lin Y.-C., Wang J.-T., Chen Y.-C., Chang S.-C. Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with Acinetobacter bacteremia. Clin Infect Dis 2011, 52:352-360.
3. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M07-A8 2008, CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 22nd information supplement, M11-S22 2012, CLSI, Wayne, PA.
5. Davies T.A., Queenan A.M., Morrow B.J., Shang W., Amsler K., He W., Lynch A.S., Pillar C., Flamm R.K. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother 2011, 66:2298-2307.
6. Giske C.G., Monnet D.L., Cars O., Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother 2008, 52:813-821. on behalf of ReAct-Action on Antibiotic Resistance.
7. Gordon N.C., Wareham D.W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010, 35:219-226.
8. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. National Healthcare Safety Network, and Participating National Healthcare Safety Network.
9. Higgins P.G., Dammhayn C., Hackel M., Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010, 65:233-238.
10. Hoban D.J., Bouchillon S.K., Dowzicky M.J. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diag Microb Infect Dis 2007, 57:423-428.
11. Kempf M., Rolain J.-M. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012, 39:105-114.
12. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008, 46:1254-1263.
13. Moffatt J.H., Harper M., Harrison P., Hale J.D.F., Vinogradov E., Seemann T., Henry R., Crane B., St Michael F., Cox A.D., Adler B., Nation R.L., Li J., Boyce J.D. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010, 54:4971-4977.
14. Sengstock D.M., Thyagarajan R., Apalara J., Mira A., Chopra T., Kaye K.S. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010, 50:1611-1616.
15. Shields R.K., Kwak E.J., Potoski B.A., Doi Y., Adams-Haduch J.M., Silviera F.P., Toyoda Y., Pilewski J.M., Crespo M., Pasculle A.W., Clancy C.J., Nguyen M.H. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diag Microb Infectious Dis 2011, 70:246-252.
16. Sunenshine R.H., Wright M.-O., Maragakis L.L., Harris A.D., Song X., Hebden J., Cosgrove S.E., Anderson A., Carnell J., Jernigan D.B., Kleinbaum D.G., Perl T.M., Standiford H.C., Srinivasan A. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
17. Towner K.J. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 2009, 73:355-363.